Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O14796
UPID:
SH21B_HUMAN
Alternative names:
EWS/FLI1-activated transcript 2
Alternative UPACC:
O14796; B2RBN6; Q5T0L1; Q8NI18; Q969K9
Background:
SH2 domain-containing protein 1B, also known as EWS/FLI1-activated transcript 2, plays a pivotal role in immune regulation. It acts as a cytoplasmic adapter that regulates receptors of the signaling lymphocytic activation molecule (SLAM) family, including CD84, SLAMF1, LY9, and CD244. This protein is essential in controlling signal transduction through CD244/2B4, influencing natural killer (NK) cell functions without affecting tyrosine phosphorylation. Its involvement extends to regulating CD40-induced cytokine production in dendritic cells, highlighting its significance in immune response modulation.
Therapeutic significance:
Understanding the role of SH2 domain-containing protein 1B could open doors to potential therapeutic strategies, particularly in enhancing immune responses and developing treatments for immune-related disorders.